PDCD1 and metastatic melanoma: In a phase I clinical trial, 10 metastatic melanoma patients with confirmed progression on PD-1-targeted immunotherapy received FMT from donors with metastatic melanoma who had achieved complete remission for at least 12 months with PD-1-targeted immunotherapy.